GlassScriptPhysician profile
David P Williams
NPI 1750355962
$14,763.09
in general payments reported to CMS, 2019-2025
71 companies · $3,160 in 2025
The $3,160 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,078 · 2020: $470 · 2021: $860 · 2022: $2,136 · 2023: $2,983 · 2024: $3,077 · 2025: $3,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,714 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $155 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,714.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $155.00 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,362.73 | 2021-2025 | Botox, Qulipta, Duopa |
| Ucb, INC. | $1,319.21 | 2019-2025 | Zilbrysq, Rystiggo, Nayzilam |
| Pfizer INC. | $899.38 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $711.06 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $697.50 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $634.16 | 2019-2025 | |
| Amgen INC. | $490.22 | 2019-2025 | Uplizna |
| Grifols USA, LLC | $488.35 | 2019-2025 | Gamunex-C |
| Lundbeck LLC | $442.90 | 2021-2025 | Vyepti |
| Acadia Pharmaceuticals INC | $435.88 | 2019-2025 | Nuplazid |
| Celgene Corporation | $406.32 | 2022-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $364.81 | 2019-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $344.98 | 2019-2025 | Enspryng, Evrysdi, Ocrevus |
| Genzyme Corporation | $333.71 | 2019-2025 | |
| Mdd US Operations, LLC | $333.52 | 2020-2025 | Gocovri |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.